Previous 10 | Next 10 |
Remark Holdings (NASDAQ:MARK) +266%. Sonim Technologies (NASDAQ:SONM) +96%. Creatd (NASDAQ:CRTD) +69% announces second NFT drop, includes photographs of former President Donald Trump PAE Incorporated (NASDAQ:PAE) +67% Amentum to buy PAE in an all-cash deal valued at ~$1.9 ...
Progression Free Survival of 7 months after Treatment with KiroVAX/BSK01 and Chemotherapy Versus 3.9 months with Standard of Care KiroVax/BSK01 Underscores the Company’s Cellular Therapy Approach to Treating Solid Cancer Tumors Advancement of KiroVax/BSK01 Lev...
Alexis ISO-1 is Company’s First Artificial Intelligence-identified, Gamma Delta T Cell Engineered Iso-Mesothelin Candidate to Address Solid Tumor Cancers Company Also Provides Guidance on Regulatory Pathway Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“...
Daniel Clark Appointed as Interim Chief Financial Officer Mr. Clark Previously Served as Kiromic’s Corporate Controller and Vice President of Finance Operations Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”...
Gainers: ProQR Therapeutics (NASDAQ:PRQR) +22%, Centessa Pharmaceuticals CNTA +22%, Kiromic BioPharma (NASDAQ:KRBP) +19%, Trinity Biotech TRIB +16%, Enveric Biosciences (NASDAQ:ENVB) +14%. Losers: Humanigen HGEN -54%, Invacare IVC -34%,...
Kiromic Operating Highlights of 2Q-2021 Kiromic BioPharma (NASDAQ: KRBP) , a pre-clinical stage biotechnology company using its proprietary DIAMOND ® artificial intelligence (“A.I.”) platform to improve drug discovery and development with a therape...
ktsimage/iStock via Getty Images Kiromic Biopharma (KRBP) has completed the acquisition of InSilico Solutions. Shares rally 33% after-hours. Yesterday's close was $3.13. With this acquisition, Kiromic will bring in-house a team of experts in bio-informatics and artificial intelligen...
Kiromic Biopharma, Inc. (Nasdaq: KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/ne...
Kiromic BioPharma, Inc. (Nasdaq: KRBP) Two INDs were submitted to the FDA in May 2021 for the first-in-human off-the-shelf allogeneic CAR-T for Solid Tumors. FDA returned with comments on the Company’s allogeneic CAR-T products with respect to: -- Tracing of all reage...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Seeking Alpha wishes our subscribers a beautiful holiday weekend and a Happy Fourth of July! Wall Street Breakfast won't be published with markets closed o...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
OTCMKTS Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...